Wegovy, Ozempic & Mounjaro Weight Loss Injections Available in the UK
Bradford, UK, July 24, 2024 — Heart disease remains the leading cause of death in the UK, claiming over 160,000 lives annually. While advancements in treatment exist, preventing heart attacks is a crucial public health goal. Exciting new research suggests a potential game-changer: a weight-loss medication showing promise in reducing heart attack risk even in patients who don’t lose significant weight.
Semaglutide: A Potential Weapon Against Heart Disease
Recent studies published on semaglutide, a weight-loss jab that mimics a natural gut hormone regulating appetite and blood sugar shown to benefit the cardiovascular system. It’s available under two brand names: Ozempic for type 2 diabetes and Wegovy for weight management. Both are administered weekly.
Landmark Trial Shows Weight Loss and Heart Benefits
The Semaglutide and Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial studied over 9,500 participants. Those taking semaglutide lost an average of 15% of their body weight after two years, and crucially, experienced a 26% decrease in major adverse cardiovascular events (MACE) like heart attacks and strokes.
A recent analysis of this data suggests semaglutide offers heart benefits beyond weight loss. Even patients who lost little weight or gained weight on semaglutide seemed to experience similar reductions in heart attack, stroke, and heart failure risk.
Mechanism of Action Still Under Investigation
The exact reasons for semaglutide’s heart benefits are still being explored. Potential explanations include improved blood sugar control, reduced blood pressure, and anti-inflammatory properties.
Semaglutide: A Promising Tool, But More Research Needed
The SELECT trial results are promising. Semaglutide offers a powerful tool for weight management and potentially reduces heart attack risk. However, further research is needed to determine its effectiveness in broader populations, long-term safety, and how it interacts with other medications and lifestyle interventions.
Overall, semaglutide represents a significant advancement in the fight against heart disease. The research offers hope for a future.
PRIMAN, your trusted digital ally in men’s health. Our clinic is more than just a service; it’s a beacon of empowerment, guiding men towards a healthier, happier life. With a focus on accessibility and evidence-based care, Priman offers tailored treatments for common concerns like weight management, erectile dysfunction, and hair loss.
Our ethos revolves around proactive healthcare, blending prevention, education, and treatment seamlessly. We’re not just here to treat symptoms; we’re here to equip you with the knowledge and tools to thrive.
Media Contact:
Thivera Chandrapala
Priman
London, UK
http://www.priman.co/